The Gabrail Cancer Center currently has many Clinical Trial opportunities . For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or via email
CSmith@GabrailCancerCenter.com.
An open-label randomized phase 2 trial of SAR439859, versus endocrine monotherapy as per physician’s choice in premenopausal and postmenopausal patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer with prior exposure to hormonal therapies
A GLOBAL, MULTICENTER, THREE ARMS, OPEN-LABEL RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NANOSOMAL DOCETAXEL LIPID SUSPENSION COMPARED TO TAXOTERE (DOCETAXEL INJECTION CONCENTRATE) IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE TO PRIOR CHEMOTHERAPY
An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Return to Clinical Trials at GCC
